LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical and med-tech company advancing cancer treatments, announced the appointment of Sidney Braun as Chief Executive Officer of its...
BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused...
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor...
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various...
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is leading efforts in addressing some of the pressing challenges in cancer treatment. “Instead of developing standalone...
Despite decades of progress in oncology, many cancers remain resistant to treatment, not because therapies are unavailable, but because tumor cells adapt. Immunotherapies and chemotherapies can produce...
LIXTE Biotechnology (NASDAQ: LIXT) is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone cancer...
LIXTE Biotechnology Holdings (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event inspired by the music, legacy, and lived experiences of De La Soul...
Event Sponsored by LIXTE Biotechnology Holdings, Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences...
BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a...